UK Guidance: Clinical trials for medicines: Guidance on Compliance with ICH E6 Good Clinical Practice (GCP) in the United Kingdom

Sharan Murugan
Apr 16
3 min read

The UK regulatory framework for clinical trials is undergoing a significant transition with the adoption of updated Good Clinical Practice (GCP) standards aligned with international expectations. The Medicines and Healthcare products Regulatory Agency (MHRA) is reinforcing compliance with ICH E6 (R3) to ensure high standards of participant safety, data integrity, and efficient trial conduct.

The guidance Clinical trials for medicines: Guidance on compliance with ICH E6 Good Clinical Practice (GCP) in the United Kingdom reflects these updates and supports implementation of the revised framework, including provisions applicable from 28 April 2026.

The revised framework reflects evolving clinical trial methodologies, including decentralised trials and advanced data systems, while maintaining a strong emphasis on participant protection and data reliability.

Compliance with ICH E6 GCP in the United Kingdom

All clinical trials involving investigational medicinal products in the UK must comply with ICH E6 GCP principles, as embedded within UK legislation. Compliance ensures that trials are designed, conducted, recorded, and reported in a way that protects participants and ensures credible data.

Sponsors, investigators, and all delegated parties are responsible for adhering to these principles throughout the trial lifecycle, including planning, execution, monitoring, and reporting.

Training in ICH E6 GCP

Appropriate training in GCP is essential for all individuals involved in clinical trials. Personnel must be adequately qualified through education, training, and experience to perform their roles effectively.

Training programmes should be proportionate to the responsibilities of each role and should ensure that staff understand both general GCP principles and trial-specific requirements. Continuous training is encouraged to keep pace with evolving regulatory expectations and trial methodologies.

United Kingdom-Specific GCP Principles

While aligned with international standards, the UK framework includes specific expectations tailored to national regulatory requirements. These principles emphasize:

Protection of trial participants
Scientific integrity and reliability of data
Clear roles and responsibilities for sponsors and investigators
Effective oversight and governance of clinical trials

These UK-specific elements ensure that global standards are applied within the context of the UK healthcare and regulatory environment.

Disapplication and Interpretation of ICH E6 Annexes

Certain aspects of the ICH E6 GCP annexes may not apply to all clinical trials, particularly those not intended to support marketing authorisation applications.

In such cases, specific provisions may be disapplied or interpreted differently, provided that participant safety and data integrity are not compromised. This flexibility allows the guidance to be applied appropriately across different types of studies, including academic or exploratory research.

Proportional Application of GCP Principles

The guidance emphasizes a proportional approach to applying GCP requirements, ensuring that the level of oversight, documentation, and monitoring is aligned with the level of risk associated with the trial.

Lower-risk trials may require simplified processes, while higher-risk or complex trials demand more stringent controls. This approach reduces unnecessary administrative burden while maintaining regulatory compliance and participant safety.

Implementation of ICH E6 (R3) for Ongoing Trials

For trials that are already ongoing as of 28 April 2026, the transition to ICH E6 (R3) should be managed carefully. Sponsors are expected to assess ongoing trials and determine how the updated principles should be applied.

Implementation should be pragmatic, ensuring that changes do not disrupt trial integrity while gradually aligning with updated requirements. Documentation of decisions and justifications is important to demonstrate compliance during inspections.